Tarar Z, Farooq U, Inayat F, Basida S, Ibrahim F, Gandhi M
World J Exp Med. 2024; 14(4):98543.
PMID: 39713070
PMC: 11551700.
DOI: 10.5493/wjem.v14.i4.98543.
Lu X, Zhang W, Yang X, Yan X, Hussain Z, Wu Q
Transl Oncol. 2024; 50:102136.
PMID: 39369581
PMC: 11491965.
DOI: 10.1016/j.tranon.2024.102136.
Park Y, Jung J, Han S, Kim G
Aliment Pharmacol Ther. 2024; 60(11-12):1599-1608.
PMID: 39304991
PMC: 11599781.
DOI: 10.1111/apt.18286.
Wang Q, Wang L, Hao R, Zhang L, Wang W, Xia L
Front Endocrinol (Lausanne). 2024; 15:1419964.
PMID: 39280015
PMC: 11393784.
DOI: 10.3389/fendo.2024.1419964.
Lin X, Bao S, Yu Y, Huang H, Shu M
J Health Popul Nutr. 2024; 43(1):134.
PMID: 39217400
PMC: 11366125.
DOI: 10.1186/s41043-024-00618-z.
MASLD-Related Hepatocarcinoma: Special Features and Challenges.
Yague-Caballero C, Casas-Deza D, Pascual-Oliver A, Espina-Cadena S, Arbones-Mainar J, Bernal-Monterde V
J Clin Med. 2024; 13(16).
PMID: 39200802
PMC: 11354930.
DOI: 10.3390/jcm13164657.
Cross-continental insights into liver cancer: an East West epidemiology.
Meerun M, Guiu B
Hepatobiliary Surg Nutr. 2024; 13(4):739-741.
PMID: 39175742
PMC: 11336519.
DOI: 10.21037/hbsn-24-195.
A Machine Learning Model to Predict Risk for Hepatocellular Carcinoma in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.
Sarkar S, Alurwar A, Ly C, Piao C, Donde R, Wang C
Gastro Hep Adv. 2024; 3(4):498-505.
PMID: 39131709
PMC: 11307858.
DOI: 10.1016/j.gastha.2024.01.007.
Risk of incident type 2 diabetes in male NAFLD and NAFLD-free smokers: a 7-year post-cessation study.
Xie J, Lin P, Hou L, Miao M, Zhu Z, Li Y
Diabetol Metab Syndr. 2024; 16(1):192.
PMID: 39118126
PMC: 11308574.
DOI: 10.1186/s13098-024-01435-4.
Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carcinoma and Incident or Decompensated Cirrhosis: A....
Kim G, Jeong S, Jang H, Lee D, Joo S, Kim W
Liver Cancer. 2024; 13(4):426-437.
PMID: 39114758
PMC: 11305668.
DOI: 10.1159/000535943.
Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients.
Argenziano M, Kim M, Montori M, Di Bucchianico A, Balducci D, Ahn S
Hepatol Int. 2024; 18(Suppl 2):922-940.
PMID: 39012579
DOI: 10.1007/s12072-024-10692-4.
Aspirin suppresses hepatocellular carcinoma progression by inhibiting platelet activity.
Zhao L, Wang Z, Liu W, Yu L, Qi H, Ren J
World J Gastrointest Oncol. 2024; 16(6):2742-2756.
PMID: 38994144
PMC: 11236245.
DOI: 10.4251/wjgo.v16.i6.2742.
Exposure of benzo[a]pyrene induces HCC exosome-circular RNA to activate lung fibroblasts and trigger organotropic metastasis.
Mu W, Gu P, Li H, Zhou J, Jian Y, Jia W
Cancer Commun (Lond). 2024; 44(7):718-738.
PMID: 38840551
PMC: 11260768.
DOI: 10.1002/cac2.12574.
Circulating fatty acids and risk of hepatocellular carcinoma and chronic liver disease mortality in the UK Biobank.
Liu Z, Huang H, Xie J, Xu Y, Xu C
Nat Commun. 2024; 15(1):3707.
PMID: 38697980
PMC: 11065883.
DOI: 10.1038/s41467-024-47960-8.
Endotoxemia and Platelets: 2 Players of Intrahepatic Microthrombosis in NAFLD.
Violi F, Pastori D, Pignatelli P, Cammisotto V
JACC Basic Transl Sci. 2024; 9(3):404-413.
PMID: 38559621
PMC: 10978333.
DOI: 10.1016/j.jacbts.2023.07.003.
Recent advances in age-related metabolic dysfunction-associated steatotic liver disease.
He Q, Li Y, Zhao L, Lin C, Yu C, Wang D
World J Gastroenterol. 2024; 30(7):652-662.
PMID: 38515956
PMC: 10950625.
DOI: 10.3748/wjg.v30.i7.652.
Caffeine in Hepatocellular Carcinoma: Cellular Assays, Animal Experiments, and Epidemiological Investigation.
Shan L, Zhao N, Wang F, Zhai D, Liu J, Lv X
J Inflamm Res. 2024; 17:1589-1605.
PMID: 38495344
PMC: 10941793.
DOI: 10.2147/JIR.S424384.
The Influence of Diet and Its Components on the Development and Prevention of Hepatocellular Carcinoma (HCC).
Janota B, Szymanek B
Cancers (Basel). 2024; 16(5).
PMID: 38473387
PMC: 10930424.
DOI: 10.3390/cancers16051030.
Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma.
Wang J, Liu C, Hu R, Wu L, Li C
Front Pharmacol. 2024; 15:1324140.
PMID: 38362156
PMC: 10867224.
DOI: 10.3389/fphar.2024.1324140.
From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention.
Motta B, Masarone M, Torre P, Persico M
Cancers (Basel). 2023; 15(22).
PMID: 38001718
PMC: 10670704.
DOI: 10.3390/cancers15225458.